CalciMedica, Inc. 8-K

What Happened

• On January 28, 2026, CalciMedica, Inc. (filed as Item 8.01 on Form 8-K) announced it has discontinued its Phase 2 KOURAGE clinical trial following a recommendation from the trial’s Independent Data Monitoring Committee.
• As a result of reducing planned operating expenses tied to the trial discontinuation, the company updated its financial guidance: it now expects existing cash, cash equivalents, and short-term investments to be sufficient to fund the current operating plan into the fourth quarter of 2026 (previous guidance: the second half of 2026). The report is signed by CEO A. Rachel Leheny, Ph.D.

Key Details

• Filing date: January 28, 2026 (Form 8-K, Item 8.01).
• Trial affected: Phase 2 KOURAGE — discontinued per Independent Data Monitoring Committee recommendation.
• Updated cash runway: now expected to last into Q4 2026 versus prior guidance of the second half of 2026.
• Company cites forward-looking statement risks and refers investors to Risk Factors in its Form 10-Q for the quarter ended Sept. 30, 2025 (filed Nov. 12, 2025).

Why It Matters

• Stopping the KOURAGE trial is a material operational change that reduces near-term clinical spending and directly drove the extension of CalciMedica’s cash runway.
• For investors, the update affects timelines for the company’s clinical development activities and the pace at which the company may need additional capital; the company did not disclose trial results or reasons beyond the IDMC recommendation in this filing.
• The filing includes standard forward-looking statement cautions; actual outcomes (including future funding needs or development plans) may differ.